TrialDiabetes care2025

Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial).

Rajiv Agarwal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.